Veracyte Acquires Convergent Genomics for $150 Million Cash Plus Up to $30 Million Earnout
Veracyte entered into an Agreement and Plan of Merger to acquire Convergent Genomics, adding the UroAmp test and urine tumor DNA technology to its portfolio. The deal closed on September 14, 2026, with $150 million paid in cash at closing and up to $30 million in additional cash tied to milestones…
Veracyte entered into an Agreement and Plan of Merger to acquire Convergent Genomics, adding the UroAmp test and urine tumor DNA technology to its portfolio. The deal closed on September 14, 2026, with $150 million paid in cash at closing and up to $30 million in additional cash tied to milestones…